Polyamidoamine-based nanovector for the efficient delivery of methotrexate to U87 glioma cells

Natalia Ortiz; Pilar A. Vásquez; Felipe Vidal; Carola F. Díaz; José L. Guzmán; Verónica A. Jiménez; Joel B. Alderete

doi:10.2217/nnm-2020-0305

Polyamidoamine-based nanovector for the efficient delivery of methotrexate to U87 glioma cells

Natalia Ortiz, Pilar A. Vásquez, Felipe Vidal, Carola F. Díaz, José L. Guzmán, Verónica A. Jiménez, Joel B. Alderete

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

The purpose of this study was to design a polyamidoamine (PAMAM)-based nanovector for the efficient delivery of methotrexate to U87 glioma cells. To this end, 0-100% acetylated PAMAM dendrimers of the fourth generation were synthesized and evaluated using drug encapsulation measurements, molecular dynamics simulations, neurotoxicity assays and neuronal internalization experiments. The best system was tested as a nanovector for methotrexate delivery to U87 glioma cells. The authors found that 25% acetylated PAMAM dendrimers of the fourth-generation combine low intrinsic toxicity, large drug complexation capacity and efficient internalization into hippocampal neurons. Nanovector complexation enhances the cytotoxic response of methotrexate against U87 glioma cells compared with free drug solutions. In conclusion, 25% acetylated PAMAM dendrimers of the fourth-generation increase drug uptake by glioma cells and thereby act as efficient nanovectors for methotrexate delivery.

Original language	English
Pages (from-to)	2771-2784
Number of pages	14
Journal	Nanomedicine (London, England)
Volume	15
Issue number	28
DOIs	https://doi.org/10.2217/nnm-2020-0305
Publication status	Published - 1 Dec 2020

Keywords

dendrimer-based delivery
glioma targeting
methotrexate
nanovector

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Biomedical Engineering
General Materials Science

Access to Document

10.2217/nnm-2020-0305

Cite this

@article{1a44ddc1b0104d9da6133cfac68b1014,

title = "Polyamidoamine-based nanovector for the efficient delivery of methotrexate to U87 glioma cells",

abstract = "The purpose of this study was to design a polyamidoamine (PAMAM)-based nanovector for the efficient delivery of methotrexate to U87 glioma cells. To this end, 0-100% acetylated PAMAM dendrimers of the fourth generation were synthesized and evaluated using drug encapsulation measurements, molecular dynamics simulations, neurotoxicity assays and neuronal internalization experiments. The best system was tested as a nanovector for methotrexate delivery to U87 glioma cells. The authors found that 25% acetylated PAMAM dendrimers of the fourth-generation combine low intrinsic toxicity, large drug complexation capacity and efficient internalization into hippocampal neurons. Nanovector complexation enhances the cytotoxic response of methotrexate against U87 glioma cells compared with free drug solutions. In conclusion, 25% acetylated PAMAM dendrimers of the fourth-generation increase drug uptake by glioma cells and thereby act as efficient nanovectors for methotrexate delivery.",

keywords = "dendrimer-based delivery, glioma targeting, methotrexate, nanovector",

author = "Natalia Ortiz and V{\'a}squez, {Pilar A.} and Felipe Vidal and D{\'i}az, {Carola F.} and Guzm{\'a}n, {Jos{\'e} L.} and Jim{\'e}nez, {Ver{\'o}nica A.} and Alderete, {Joel B.}",

note = "Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine",

year = "2020",

month = dec,

day = "1",

doi = "10.2217/nnm-2020-0305",

language = "English",

volume = "15",

pages = "2771--2784",

journal = "Nanomedicine (London, England)",

issn = "1743-5889",

publisher = "Taylor and Francis Ltd.",

number = "28",

}

TY - JOUR

T1 - Polyamidoamine-based nanovector for the efficient delivery of methotrexate to U87 glioma cells

AU - Ortiz, Natalia

AU - Vásquez, Pilar A.

AU - Vidal, Felipe

AU - Díaz, Carola F.

AU - Guzmán, José L.

AU - Jiménez, Verónica A.

AU - Alderete, Joel B.

N1 - Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine

PY - 2020/12/1

Y1 - 2020/12/1

N2 - The purpose of this study was to design a polyamidoamine (PAMAM)-based nanovector for the efficient delivery of methotrexate to U87 glioma cells. To this end, 0-100% acetylated PAMAM dendrimers of the fourth generation were synthesized and evaluated using drug encapsulation measurements, molecular dynamics simulations, neurotoxicity assays and neuronal internalization experiments. The best system was tested as a nanovector for methotrexate delivery to U87 glioma cells. The authors found that 25% acetylated PAMAM dendrimers of the fourth-generation combine low intrinsic toxicity, large drug complexation capacity and efficient internalization into hippocampal neurons. Nanovector complexation enhances the cytotoxic response of methotrexate against U87 glioma cells compared with free drug solutions. In conclusion, 25% acetylated PAMAM dendrimers of the fourth-generation increase drug uptake by glioma cells and thereby act as efficient nanovectors for methotrexate delivery.

AB - The purpose of this study was to design a polyamidoamine (PAMAM)-based nanovector for the efficient delivery of methotrexate to U87 glioma cells. To this end, 0-100% acetylated PAMAM dendrimers of the fourth generation were synthesized and evaluated using drug encapsulation measurements, molecular dynamics simulations, neurotoxicity assays and neuronal internalization experiments. The best system was tested as a nanovector for methotrexate delivery to U87 glioma cells. The authors found that 25% acetylated PAMAM dendrimers of the fourth-generation combine low intrinsic toxicity, large drug complexation capacity and efficient internalization into hippocampal neurons. Nanovector complexation enhances the cytotoxic response of methotrexate against U87 glioma cells compared with free drug solutions. In conclusion, 25% acetylated PAMAM dendrimers of the fourth-generation increase drug uptake by glioma cells and thereby act as efficient nanovectors for methotrexate delivery.

KW - dendrimer-based delivery

KW - glioma targeting

KW - methotrexate

KW - nanovector

UR - http://www.scopus.com/inward/record.url?scp=85097211110&partnerID=8YFLogxK

U2 - 10.2217/nnm-2020-0305

DO - 10.2217/nnm-2020-0305

M3 - Article

C2 - 33073670

AN - SCOPUS:85097211110

SN - 1743-5889

VL - 15

SP - 2771

EP - 2784

JO - Nanomedicine (London, England)

JF - Nanomedicine (London, England)

IS - 28

ER -

Polyamidoamine-based nanovector for the efficient delivery of methotrexate to U87 glioma cells

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this